Nektar Therapeutics preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.
Thank you, Crystal. Welcome, everyone, and thank you for joining us on today's call. Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's proprietary drug candidate, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks which are detailed in our filings with the SEC, including the Form 10-Q filed on August 9, 2019. We undertake no obligation to update these forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
